The Estonian Standardization and Accreditation Center conducted a regular audit in 2026 and confirms that Asper Biogene OÜ meets the requirements of EVS-EN ISO 15189:2022 as a medical laboratory in the field of genetics. Into the list of accredited tests were added:
- Determination of thrombophilia-related changes using NGS analysis,
- Determination of hypolactasia-related changes using NGS and Sanger analysis
Genes associated with neuroacanthocytosis were added to dystonia and Parkinson disease panels
Monogenic obesity gene panel was added to Asper Metabolic Disorders portfolio. See also galactosemia, lactose intolerance and celiac disease.
The analysis of familial hypercholesterolaemia now includes 8 genes.
Myotonia Congenita NGS panel was added into Asper Biogene’s Neurogenetics portfolio
There have been several updates among Asper Cardiogenetics
We have a brand new portfolio!
Asper Dysmorphology now offer panels for Joubert Syndrome, Ehler-Danlos Syndrome, Bardet-Biedli Syndrome and many more.
The Cardiogenetics, Metabolic Disorders, and Otogenetics panels now offer mitochondrial genome sequencing.